Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18810302 | 1.00 | MAPT (0.40) | MAPTALDH1A1KDM4EMEN1GAA | |
| SCHEMBL17057064 | 1.00 | MAPT (0.40) | MAPTALDH1A1KDM4EMEN1GAA | |
| SCHEMBL2504163 | 1.00 | MAPT (0.40) | MAPTALDH1A1KDM4EMEN1GAA | |
| SCHEMBL22728078 | 1.00 | MAPT (0.40) | MAPTALDH1A1KDM4EMEN1GAA | |
| SCHEMBL17057061 | 1.00 | MAPT (0.40) | MAPTALDH1A1KDM4EMEN1GAA | |
| SCHEMBL2504165 | 1.00 | MAPT (0.40) | MAPTALDH1A1KDM4EMEN1GAA | |
| SCHEMBL7633072 | 0.87 | MAPT (0.40) | MAPTALDH1A1KDM4EMEN1GAA | |
| SCHEMBL9623268 | 0.86 | MAPT (0.41) | MAPTALDH1A1KDM4EMEN1GAA | |
| SCHEMBL11827403 | 0.84 | ALDH1A1 (0.42) | MAPTALDH1A1KDM4EMEN1GAA | |
| SCHEMBL1536076 | 0.84 | ALDH1A1 (0.42) | MAPTALDH1A1KDM4EMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417386-A1 | INHIBITORS OF RET | MIDCAP FINANCIAL TRUST | 2024-12-19 | — | — | US | disclosed |
| EP-4331585-A2 | INHIBITORS OF RET | Blueprint Medicines Corporation (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4292594-A2 | INHIBITORS OF RET | Blueprint Medicines Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-3371171-B1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-111423416-B | Inhibitors of RET | 缆图药品公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20220315560-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION | 2022-10-06 | — | — | US | disclosed |
| US-11279688-B2 | Inhibitors of RET | BLUEPRINT MEDICINES CORPORATION (US) | 2022-03-22 | — | — | US | disclosed |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-20200407341-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION | 2020-12-31 | — | — | US | disclosed |
| CN-111423416-A | Inhibitors of RET | 蓝图药品公司 | 2020-07-17 | — | — | CN | disclosed |
| US-20160060256-A1 | THIAZOLE-SUBSTITUTED AMINOPYRIMIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | US | disclosed |
| US-9120785-B2 | Pyridyl aminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | ALTMAN MICHAEL D (US) | 2014-08-28 | — | — | US | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140100250-A1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-04-10 | — | — | US | disclosed |
| EP-2707357-A1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| WO-2012154520-A1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | MAPT 3486/4885ALDH1A1 1614/4885KDM4E 715/4885 |
| US-20240417386-A1 | INHIBITORS OF RET | RET, HRAS, RB1 | MAPT 1447/4885ALDH1A1 3153/4885KDM4E 1083/4885 |
| US-20160060256-A1 | THIAZOLE-SUBSTITUTED AMINOPYRIMIDINES AS SPLEEN TYROSINE KINASE INHIBITORS | SYK, BTK, LCK | MAPT 3482/4885ALDH1A1 2709/4885KDM4E 1171/4885 |
| US-11279688-B2 | Inhibitors of RET | RET, HRAS, RB1 | MAPT 1447/4885ALDH1A1 3153/4885KDM4E 1083/4885 |
| US-20140100250-A1 | PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS | SYK, BTK, LCK | MAPT 4250/4885ALDH1A1 1683/4885KDM4E 689/4885 |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | SYK, BTK, LCK | MAPT 3486/4885ALDH1A1 1614/4885KDM4E 715/4885 |
| US-20200407341-A1 | INHIBITORS OF RET | RET, HRAS, RB1 | MAPT 1447/4885ALDH1A1 3153/4885KDM4E 1083/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | MAPT 4508/4885ALDH1A1 2898/4885KDM4E 2686/4885 |
| US-20220315560-A1 | INHIBITORS OF RET | RET, HRAS, RB1 | MAPT 1447/4885ALDH1A1 3153/4885KDM4E 1083/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | MAPT 3486/4885ALDH1A1 1614/4885KDM4E 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.